Search Results - Nelson Fontanez
- Showing 1 - 3 results of 3
-
1
Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus by Kazunori Nagashima, C.S. Lopez, Daniel Donovan, Colleen Ngai, Nelson Fontanez, André Bensadoun, Jamila Fruchart‐Najib, Steve Holleran, Jeffrey S. Cohn, Rajasekhar Ramakrishnan, Henry N. Ginsberg
Published 2005Artigo -
2
Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus by Kazunori Nagashima, C.S. Lopez, Daniel Donovan, Colleen Ngai, Nelson Fontanez, André Bensadoun, Jamila Fruchart‐Najib, Steve Holleran, Jeffrey S. Cohn, Rajasekhar Ramakrishnan, Henry N. Ginsberg
Published 2005Artigo -
3
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans by Gissette Reyes‐Soffer, Marianna Pavlyha, Colleen Ngai, Tiffany Thomas, Stephen Holleran, Rajasekhar Ramakrishnan, Wahida Karmally, Renu Nandakumar, Nelson Fontanez, Joseph C. Obunike, Santica M. Marcovina, Alice H. Lichtenstein, Nirupa R. Matthan, James F. Matta, M. Maroccia, Frederic Becue, Franck Poitiers, Brian N. Swanson, Lisa N. Cowan, William J. Sasiela, Howard K. Surks, Henry N. Ginsberg
Published 2016Artigo
Search Tools:
Related Subjects
Apolipoprotein B
Cholesterol
Endocrinology
Internal medicine
Lipoprotein
Medicine
Very low-density lipoprotein
Adipose tissue
Chemistry
Diabetes mellitus
Lipolysis
Lipoprotein lipase
Pioglitazone
Type 2 diabetes
Alirocumab
Apolipoprotein A1
Evolocumab
Insulin
Insulin resistance
Kexin
LDL receptor
Lipoprotein particle
Lipoprotein(a)
Low-density lipoprotein
PCSK9